Stroke is a leading cause of death and disability world-wide, with very few treatment options available to patients, and limited understanding of underlying comorbidities and interaction with risk. Both ischemic and hemorrhagic stroke are mostly modelled in vivo, in an attempt to characterise the damage caused by these multi-system disorders. Despite best efforts, drug discovery remains stagnant and patients are still likely to experience years of disability and long-term loss of cognitive function. New models are required to understand individual aspects of the disease, to enable broader collaborations between pre-clinical and clinical researchers, and build a more rounded picture of the multiple complex systems involved in stroke pathology.
Advances in therapeutic discovery and stroke research have been slow, and understanding the complexities underlying the pathology of the disease and its resolution remains elusive. With the innovation of novel models that recapitulate aspects of different physiology in vitro, or account for the clinically observed comorbidities in vivo, we hope to excel in the advancement of drug discovery. This research topic will address the development of novel models that can be applied to both ischemic and hemorrhagic stroke research and that can be used together to understand better the causes and outcomes of disease. We hope that researchers who previously have not considered an application in stroke research for their model, will submit to this topic to encourage new collaborations within the field and new possibilities for advancement.
We are interested in both review and original research articles that demonstrate the use of a novel approach to modelling stroke, comorbidities, or pathology. Specific themes include but are not limited to:
1. The use and development of novel model systems such as organoids, organ-on-a-chip, and complex 3D physiological models.
2. Potential applications in drug screening and discovery.
3. Identifying novel interactions in the pathological progression of the disease, within the context of studying the influence of comorbidities on stroke outcomes.
To be applicable in either ischemic or hemorrhagic stroke, we are interested in models of the blood-brain barrier, cerebrovascular disruption, novel in vitro and in vivo methods, neuroinflammation, and comorbidities with stroke as a secondary outcome such as hypertension, glucose dysregulation, cholesterol dysregulation, and morphological abnormalities. Submissions must outline a clear application to stroke and understanding of the problems faced.
Stroke is a leading cause of death and disability world-wide, with very few treatment options available to patients, and limited understanding of underlying comorbidities and interaction with risk. Both ischemic and hemorrhagic stroke are mostly modelled in vivo, in an attempt to characterise the damage caused by these multi-system disorders. Despite best efforts, drug discovery remains stagnant and patients are still likely to experience years of disability and long-term loss of cognitive function. New models are required to understand individual aspects of the disease, to enable broader collaborations between pre-clinical and clinical researchers, and build a more rounded picture of the multiple complex systems involved in stroke pathology.
Advances in therapeutic discovery and stroke research have been slow, and understanding the complexities underlying the pathology of the disease and its resolution remains elusive. With the innovation of novel models that recapitulate aspects of different physiology in vitro, or account for the clinically observed comorbidities in vivo, we hope to excel in the advancement of drug discovery. This research topic will address the development of novel models that can be applied to both ischemic and hemorrhagic stroke research and that can be used together to understand better the causes and outcomes of disease. We hope that researchers who previously have not considered an application in stroke research for their model, will submit to this topic to encourage new collaborations within the field and new possibilities for advancement.
We are interested in both review and original research articles that demonstrate the use of a novel approach to modelling stroke, comorbidities, or pathology. Specific themes include but are not limited to:
1. The use and development of novel model systems such as organoids, organ-on-a-chip, and complex 3D physiological models.
2. Potential applications in drug screening and discovery.
3. Identifying novel interactions in the pathological progression of the disease, within the context of studying the influence of comorbidities on stroke outcomes.
To be applicable in either ischemic or hemorrhagic stroke, we are interested in models of the blood-brain barrier, cerebrovascular disruption, novel in vitro and in vivo methods, neuroinflammation, and comorbidities with stroke as a secondary outcome such as hypertension, glucose dysregulation, cholesterol dysregulation, and morphological abnormalities. Submissions must outline a clear application to stroke and understanding of the problems faced.
